An initiative to apply the technology underpinning the core business to ASOs, mRNA therapeutics and ncRNA-targeting therapeutics, thereby diversifying into the nucleic acid therapeutics field and creating new pipelines. This includes obtaining drug candidates arising from research with Mitsubishi Gas Chemical and filing composition-of-matter patent applications.